Results 161 to 170 of about 1,428 (257)

Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Canagliflozin was recently approved in type 2 diabetes mellitus (T2DM) patients ≥10 and <18 years old as a single agent dosed once daily (QD) or in a fixed‐dose combination with metformin dosed twice daily (BID). We characterize canagliflozin pharmacokinetics in paediatric patients with T2DM, compare estimated individual and simulated ...
Nele Goeyvaerts, Per Olsson Gisleskog, Martine Neyens, Juan José Perez Ruixo, Saberi Rana Ali, Iolanda Cirillo, Oliver Ackaert   +6 more
wiley   +1 more source

Characterizing iconic gesture during narratives in chronic traumatic brain injury recovery. [PDF]

Front Hum Neurosci
Urena K, Stark BC.
europepmc   +1 more source

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors.
Mendy ter Avest, Simon E. Koele, Nicole C. A. J. van de Kar, Saskia M. C. Langemeijer, Rob ter Heine   +4 more
wiley   +1 more source

Where Mathematical Symbols Come From. [PDF]

Top Cogn Sci
Schlimm D.
europepmc   +1 more source

Development of a population pharmacokinetic model using combined paediatric and adult data for four pulmonary arterial hypertension drugs

British Journal of Clinical Pharmacology, EarlyView.
Aims Pulmonary arterial hypertension (PAH) is a syndrome characterized by elevated pulmonary artery pressure. We developed a population pharmacokinetic (PPK) model using combined plasma drug concentration data from Japanese paediatric (<15 years) and adult (≥15 years) patients with PAH to investigate the pharmacokinetic characteristics of PAH ...
Motoyasu Miura, Shimako Tanaka, Ririka Aihara, Shun Yamamoto, Yasumi Nakashima, Yasuharu Kashiwagura, Akio Hakamata, Sachiko Miyakawa, Mariko Tatsuguchi, Keiichi Odagiri, Noriyuki Namiki, Naoki Inui, Hiroshi Watanabe, Shinya Uchida   +13 more
wiley   +1 more source

Attention-regulation strategies used by Deaf parents of deaf autistic children: A pilot study. [PDF]

Enfance
Shield A.
europepmc   +1 more source

Polycationic Peptide Engineering of Phage Endolysins Expands Host Range and Enhances Antibacterial and Antibiofilm Activities Against Bacillus Species

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The exponential rise in antimicrobial resistance has highlighted the urgent need for the development of alternative antibacterial strategies, including phage‐derived and engineered protein agents such as endolysins and artilysins. In this study, we report the rational design, expression, and functional characterization of novel artilysins ...
Farhat Ansari, Tarushi, Vandan Nagar
wiley   +1 more source

The State-Before-Event Inference Emerges Across Tenses. [PDF]

Open Mind (Camb)
Marx E, Jardón N, Wittenberg E.
europepmc   +1 more source

Compliant hydrogel cuff coating with real‐time pressure monitoring and antibiofilm capabilities for ventilator‐associated pneumonia prophylaxis

BMEMat, EarlyView.
A soft‐compliant hydrogel cuff coating combines real‐time pressure monitoring with intrinsic antibacterial activity for prophylaxis of ventilator‐associated pneumonia. A flexible pressure‐sensing patch is embedded in the coating to enable wireless dynamic monitoring of endotracheal cuff pressure through Bluetooth.
Jin Chai, Yifu Tan, Jiaheng Liang, Shen Liu, Jiabin Zhao, Shanbo Ma, Chunxin Liu, Minghua Du, Mark Selvan, Xiaopeng Shi, Liqiang Song, Peng Li   +11 more
wiley   +1 more source

Early Production of Imperceptible Words by Infants and Toddlers Born Deaf or Blind. [PDF]

Open Mind (Camb)
Campbell EE, Davis CP, Zettersten M, Cooke M, Houston D, Caselli N, Bergelson E.   +6 more
europepmc   +1 more source